Gapping down
News:
- OLMA -26.1% (New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025)
- EXEL -12.7% (results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX)
- SMMT -5.2% (Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China)
- GMAB -4.5% (New Data Demonstrating Investigational Rinatabart Sesutecan)
- APLS -2% (New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week)
- ONC -1.6% (presents new data on Tevimbra in Lung Cancer at ESMO)
- FLGT -0.9% (shares preliminary data from poster presentation at ESMO 2025 Conference)
- AMGN -0.8% (Amgen and AstraZeneca (AZN) announce that the U.S FDA approved TEZSPIRE)
- VSTM -0.8% (Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma)
- ONCY -0.8% (entered into $50 mln At-the-Market Sales Agreement with BTIG)